Stockscreener 앱 받기
1.06
1.92%
0.02
시간 외 거래:
1.08
0.02
+1.89%
전일 마감가:
$1.04
열려 있는:
$1
하루 거래량:
912.45K
Relative Volume:
0.90
시가총액:
$113.55M
수익:
$33.03M
순이익/손실:
$-44.63M
주가수익비율:
-2.528
EPS:
-0.4193
순현금흐름:
$-36.18M
1주 성능:
+29.76%
1개월 성능:
+25.03%
6개월 성능:
-38.01%
1년 성능:
-53.91%
1일 변동 폭
$0.9986
$1.07
1주일 범위
$0.784
$1.16
52주 변동 폭
$0.6434
$2.40
맥스사이트 Stock (MXCT) Company Profile
명칭
Maxcyte Inc
전화
301-517-5556
주소
9713 KEY WEST AVENUE,, ROCKVILLE
Compare MXCT vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
1.06 | 111.41M | 33.03M | -44.63M | -36.18M | -0.4193 |
ABT
Abbott Laboratories
|
87.91 | 147.13B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
313.22 | 117.60B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
77.32 | 97.77B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
55.92 | 78.30B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
82.39 | 46.86B | 6.30B | 1.07B | 1.09B | 1.8406 |
맥스사이트 Stock (MXCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-11 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2025-08-07 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-07-22 | 개시 | Stephens | Overweight |
| 2023-11-29 | 개시 | Craig Hallum | Buy |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-08-24 | 개시 | BTIG Research | Buy |
| 2021-08-24 | 개시 | Cowen | Outperform |
| 2021-08-24 | 개시 | Stephens | Overweight |
| 2021-08-24 | 개시 | Stifel | Buy |
| 2021-08-24 | 개시 | Wedbush | Outperform |
| 2021-08-24 | 개시 | William Blair | Outperform |
모두보기
맥스사이트 주식(MXCT)의 최신 뉴스
MaxCyte, Inc. (MXCT) reports Q1 loss, tops revenue estimates - MSN
MaxCyte Inc stock (US57777K1060): recent volatility and growth hopes in cell therapy tools - AD HOC NEWS
MaxCyte outlines $30M-$32M 2026 revenue outlook as board authorizes $10M share repurchase program - MSN
MaxCyte Q1 earnings call highlights - MSN
MaxCyte (MXCT) Reports Strong Q1 2026 — Revenue $N/A, EPS BeatsExpert Entry Points - newser.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ibio (IBIO), MaxCyte (MXCT) and Atea Pharmaceuticals (AVIR) - The Globe and Mail
River Global Investors Discloses Investment in MaxCyte with 6.1% Stake - TradingView
River Global Investors builds 6.1% MaxCyte (MXCT) position with 6.53M shares - Stock Titan
Stock Market Today: Dow Jones Futures Fall, S&P 500 Gains As Trump Takes Big Tech Leaders To China—Nvidia, Nextpower, Red Cat In Focus - Sahm
Cisco, Alibaba And 3 Stocks To Watch Heading Into Wednesday - Sahm
MSN Money - MSN
MaxCyte (NASDAQ: MXCT) Q1 2026 revenue dips as expenses fall - Stock Titan
Stifel Maintains MaxCyte(MXCT.US) With Buy Rating, Maintains Target Price $4 - Moomoo
BTIG Maintains MaxCyte(MXCT.US) With Hold Rating - Moomoo
MaxCyte posts $4.8M loss, still lines up $10M stock buyback - Stock Titan
Stock Market Today: Dow Jones Futures Fall, Nasdaq Gains As Trump Takes Big Tech Leaders To China— Nvidia, Nextpower, Red Cat In Focus (UPDATED) - Benzinga
MaxCyte, Inc. (NASDAQ:MXCT) Q1 2026 Earnings Call Transcript - Insider Monkey
Here’s Why MaxCyte (MXCT) is Becoming a High-Conviction Bet for Investors - Insider Monkey
Earnings Call Summary | MaxCyte(MXCT.US) Q1 2026 Earnings Conference - Moomoo
12 Health Care Stocks Moving In Tuesday's After-Market Session - Sahm
MaxCyte Q1 Earnings Call Highlights - MarketBeat
MaxCyte, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Earnings call transcript: MaxCyte beats Q1 2026 forecasts with strong revenue By Investing.com - Investing.com South Africa
Earnings call transcript: MaxCyte beats Q1 2026 forecasts with strong revenue - Investing.com Nigeria
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
MaxCyte Reports Q1 2026 Results, Launches Share Buyback - TipRanks
MaxCyte (NASDAQ:MXCT) Q1 2026 Results Beat Estimates, Stock Rises on Buyback - ChartMill
MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance - The Manila Times
MaxCyte (NASDAQ: MXCT) Q1 2026 revenue $9.7M as board approves $10M buyback - Stock Titan
Press Release: MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance - Moomoo
MaxCyte Inc (MXCT) Q1 2026 Earnings Call Highlights: Revenue Meets Expectations Amid Core ... By GuruFocus - Investing.com Canada
MaxCyte (MXCT) price target decreased by 11.67% to 4.33 - MSN
BTIG Downgrades MaxCyte (MXCT) - MSN
MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026 - The Manila Times
MaxCyte (MXCT) price target decreased by 14.88% to 4.90 - MSN
SEC Form DEFA14A filed by MaxCyte Inc. - Quantisnow
[ARS] MAXCYTE, INC. SEC Filing - Stock Titan
Directors and auditor on ballot at MaxCyte (NASDAQ: MXCT) 2026 meeting - Stock Titan
MaxCyte schedules May 12 earnings release, 4:30 p.m. call - Stock Titan
MaxCyte (MXCT) Stock: Short-Term Trend (Technical Strength) 2026-04-27Crowd Consensus Signals - newser.com
MaxCyte announces 34% workforce reduction to cut costs - MSN
맥스사이트 (MXCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.72%
자본화:
|
볼륨(24시간):